Immunic (IMUX) Projected to Announce Earnings on Thursday

Immunic (NASDAQ:IMUX) is expected to be releasing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.7852) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 19, 2026 at 9:30 AM ET.

Immunic (NASDAQ:IMUX) last announced its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.36. On average, analysts expect Immunic to post ($3.69) EPS for the current fiscal year and ($2.61) EPS for the next fiscal year.

Immunic Trading Up 2.7%

Shares of IMUX stock opened at $7.96 on Tuesday. Immunic has a 1 year low of $5.06 and a 1 year high of $17.43. The firm’s 50 day moving average is $9.22 and its 200-day moving average is $11.50.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Zacks Research upgraded shares of Immunic from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 21st. Wall Street Zen lowered Immunic from a “hold” rating to a “sell” rating in a research report on Saturday, October 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunic in a research report on Wednesday, August 26th. Roth Capital reissued a “buy” rating on shares of Immunic in a research note on Tuesday, September 1st. Finally, Wedbush restated an “outperform” rating and set a $45.00 target price on shares of Immunic in a research report on Thursday, September 10th. Four analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Immunic currently has an average rating of “Buy” and an average target price of $35.43.

About Immunic

Immunic, Inc (NASDAQ: IMUX) is a clinical-stage biopharmaceutical company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on treatments designed to address significant unmet needs while potentially offering convenient alternatives to injectable or infusion-based therapies.

Immunic’s lead product candidate is vidofludimus calcium, formerly known as IMU-838. It is a selective oral inhibitor of dihydroorotate dehydrogenase (DHODH) being developed for multiple sclerosis, including relapsing and progressive forms of the disease.